Detail akcie NanoRepro AG, Ordinary, Vienna Stock Exchange - Cash Market online

Business Summary: Nanorepro AG is a Germany-based company active in the biotechnology sector. The Company is engaged in the research of stem cells, which are used in the medical treatment due to their ability to self-renew and differentiate to a range of specialized cell types. Nanorepro AG gathers samples of patients’ stem cells and stores them for the future use. Its portfolio also comprises OTC rapid diagnostic tests, such as OvuQUICK, an ovulation test for women; GraviQUICK, a pregnancy test; MenoQUICK, a menopause test; VagiQUICK, a vaginal yeast test; GlutenCHECK, a test to detect celiac disease; CholesterinCHECK, a test to measure the level of total cholesterol, HDL and LDL, as well as FertiQUICK, a fertility test for men.
Financial Summary: BRIEF: For the six months ended 30 June 2024, NanoRepro AG revenues increased 27% to EUR1.8M. Net loss decreased 56% to EUR1.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Fair Value Adjustments - Other Assets decrease from EUR569K (expense) to EUR0K, Interest and Similar Income increase from EUR134K to EUR382K (income).